A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
A specific plasma lipid signature associated with high triglycerides and low HDL cholesterol identifies residual CAD risk in patients with chronic coronary syndrome
Tekijät: Di Giorgi Nicoletta, Michelucci Elena, Smit Jeff M., Scholte Arthur J.H.A., El Mahdiui Mohammed, Knuuti Juhani, Buechel Ronny R., Teresinska Anna, Pizzi Maria N., Roque Albert, Poddighe Rosa, Parodi Oberdan, Pelosi Gualtiero, Caselli Chiara, Neglia Danilo, Rocchiccioli Silvia
Kustantaja: Elsevier Ireland Ltd
Julkaisuvuosi: 2021
Journal: Atherosclerosis
Tietokannassa oleva lehden nimi: Atherosclerosis
Vuosikerta: 339
Aloitussivu: 1
Lopetussivu: 11
eISSN: 1879-1484
DOI: https://doi.org/10.1016/j.atherosclerosis.2021.11.013
Background and aims
Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) define a specific lipid profile associated with residual coronary artery disease (CAD) risk independently of total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels. Aim of the present study was to assess whether TG/HDL-C ratio, coronary atherosclerosis and their change over time are characterized by a specific lipidomic profiling in stable patients with chronic coronary syndrome (CCS).
Methods
TG/HDL-C ratio was calculated in 193 patients (57.8 ± 7.6 years, 115 males) with CCS characterized by clinical, bio-humoral profiles and cardiac imaging. Patient-specific plasma targeted lipidomics was defined through a high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) strategy. Patients underwent coronary computed tomography angiography (CTA) and an individual CTA risk score, combining extent, severity, composition, and location of plaques, was calculated. All patients entered a follow-up (6.39 ± 1.17 years), including clinical, lipidomics and coronary CTA assessments.
Results
Patients were divided in groups according to baseline TG/HDL-C quartiles: IQ (<1.391), IIQ (1.392–2.000), IIIQ (2.001–3.286), and IVQ (≥3.287). A specific pattern of altered lipids, characterized by reduced plasma levels of cholesterol esters, phosphatidylcholines and sphingomyelins, was associated with higher TG/HDL-C both at baseline and follow-up (IVQ vs IQ). The CTA risk score increased over time and this lipid signature was also associated with higher CTA score at follow-up.
Conclusions
In stable CCS, a specific lipidomic signature identifies those patients with higher TG/HDL- C ratio and higher CTA score over time, suggesting possible molecular pathways of residual CAD risk not tackled by current optimal medical treatments.